home

clinical

drug-pipeline-news

Clinical

 and joined the MJH Life Sciences team in December 2019. She graduated from Youngstown State University in 2019 with a bachelor's degree in journalism and a minor in political science. Prior to graduating, Morgan worked as the editor-in-chief of her college newspaper. She went on to work as an assignment editor at a broadcast news station in Youngstown, Ohio before joining 

Videos

Nkechi Azie, MD, MBA, FIDSA, vice president of clinical development and medical affairs at SCYNEXIS, discusses the potential FDA approval of ibrexafungerp (Brexafemme; SCYNEXIS) for the prevention of recurrent vulvovaginal candidiasis. 

The future of ibrexafungerp for prevention of recurrent yeast infections

Articles

After a recent FDA approval, Mirena can be used to prevent pregnancy for up to 8 years. 

FDA expands approval of Mirena for up to 8 years

Novavax joins the growing list of COVID-19 vaccines including vaccines from Pfizer-BioNTech, Moderna, and Johnson & Johnson’s Janssen


FDA grants emergency use of Novavax COVID-19 vaccine, adjuvanted in patients 12 years and older

The FDA has approved cetrorelix acetate for injection, a generic version of Cetrotide, for the inhibition of premature luteinizing hormone surges in women undergoing controlled ovarian stimulation.

FDA approves generic cetrorelix acetate injection

Oteseconazole is a treatment option for those living with a previously unmet medical need.

Vivjoa approved for recurrent vulvovaginal candidiasis

Myovant Sciences and Pfizer announces the US Food and Drug Administration has approved Myfembree (relugolix combination tablets) for the once-daily treatment of moderate-to-severe endometriosis-associated pain. 

FDA approves Myfembree for endometriosis pain

If approved, ibrexafungerp would be the first and only approved therapy for both the treatment of vulvovaginal candidiasis (VVC) and the prevention of recurrent vulvovaginal candidiasis (RVVC).

FDA grants ibrexafungerp sNDA priority review for RVVC

You can reach her a lcarr@mjhlifesciences.com.

ObsEva plans to drop linzagolix, its leading candidate for the treatment of uterine fibroids, following concerns raised by the FDA. 

ObsEva drops linzagolix, focuses on prospects for preterm labor, IVF

Genevieve Neal-Perry, MD, PhD, sits down with Contemporary OB/GYN to discuss positive data from a recent phase 3 study evaluating fezolinetant (Astellas) for vasomotor symptoms (VMS). 

Fezolinetant making waves for VMS 

Mycovia Pharmaceuticals recently announced US availability of oteseconazole capsules for the treatment of recurrent vulvovaginal candidiasis in women without reproductive potential. 

Drug Pipeline News